N-Acetylcysteine for Zinc Phosphide Poisoning
N-acetylcysteine (NAC) should be administered as adjunctive therapy in adults with zinc phosphide poisoning, using the standard acetaminophen overdose protocol: 300 mg/kg IV over 20-21 hours (loading dose 150 mg/kg over 1 hour, followed by maintenance dosing). While the evidence base is limited and mortality benefit has not been definitively proven, NAC demonstrates significant hepatoprotective effects and a favorable safety profile that justifies its use in this life-threatening poisoning without a specific antidote.
Rationale for NAC Administration
The most recent randomized controlled trial 1 (2026) showed that while NAC did not achieve statistical significance for mortality reduction (6.7% vs 20.0%, p=0.254), there was a clinically meaningful 13.3% absolute risk reduction. More importantly, NAC produced highly significant hepatoprotective effects with median ALT of 92 IU/L versus 205 IU/L in controls (p<0.001) and AST of 48 IU/L versus 150 IU/L (p<0.001). Given zinc phosphide's mechanism of toxicity through phosphine-induced oxidative stress and mitochondrial dysfunction, NAC's antioxidant properties provide a rational therapeutic target.
Dosing Protocol
Use the FDA-approved acetaminophen overdose regimen 2:
- Loading dose: 150 mg/kg IV over 1 hour
- Second dose: 50 mg/kg IV over 4 hours
- Third dose: 100 mg/kg IV over 16 hours
- Total: 300 mg/kg over 21 hours
Dilution is mandatory - NAC is hyperosmolar (2600 mOsmol/L) and must be diluted in sterile water, 0.45% saline, or D5W before administration 2.
When to Extend Treatment
Consider continuing NAC beyond 21 hours if 2:
- Liver transaminases continue rising
- Patient develops signs of hepatotoxicity
- Massive ingestion occurred
- Clinical deterioration persists
Monitor ALT/AST, INR, creatinine, and electrolytes throughout treatment. Contact poison control (1-800-222-1222) for guidance on extended dosing 2.
Supporting Evidence
Multiple case reports demonstrate NAC's utility in zinc phosphide poisoning. A Hungarian case 3 documented successful recovery using NAC combined with alpha-lipoic acid in a patient with severe multi-organ failure and hepatic damage (pseudocholinesterase 706 U/L rising sixfold with treatment). Two additional cases 4 reported successful management of hepatotoxicity following zinc phosphide poisoning with NAC therapy.
The aluminum phosphide literature 5 provides additional mechanistic support, showing NAC significantly reduces oxidative stress markers (MDA) and improves total antioxidant capacity in phosphide poisoning, though the clinical manifestations differ between aluminum and zinc phosphide.
Critical Caveats
NAC is NOT indicated for methemoglobinemia - A controlled trial 6 definitively showed NAC did not reduce sodium nitrite-induced methemoglobinemia. If methemoglobinemia develops from zinc phosphide, use methylene blue (1-2 mg/kg) instead 7.
Monitor for hypersensitivity reactions 2 - Acute reactions (rash, hypotension, wheezing) can occur 30-60 minutes after infusion starts. Temporarily stop infusion, treat with antihistamines, then cautiously restart. One asthmatic patient died from bronchospasm with IV NAC; use extreme caution in asthmatics.
NAC is adjunctive only - Continue aggressive supportive care including gastrointestinal decontamination (if early presentation), hemodynamic support, correction of metabolic acidosis, and management of multi-organ dysfunction 8.
Clinical Algorithm
- Immediate: Start standard supportive care + gastrointestinal decontamination if <2 hours post-ingestion
- Within first hour: Initiate NAC 150 mg/kg IV loading dose (properly diluted)
- Monitor: Vital signs, liver enzymes, renal function, acid-base status, electrolytes
- Complete: Full 21-hour NAC protocol unless contraindicated
- Reassess at 21 hours: Check ALT/AST/INR - extend NAC if worsening
- Escalate: Contact poison control for deteriorating patients or dosing questions
The absence of a specific antidote for zinc phosphide poisoning, combined with NAC's demonstrated hepatoprotective effects, excellent safety profile (when properly administered), and potential mortality benefit, makes it a reasonable and recommended adjunctive therapy that should be started early in the clinical course.